Combined therapy with ramipril and simvastatin has beneficial additive effects on tissue factor activity and prothrombin fragment 1 + 2 in patients with type 2 diabetes

Atherosclerosis

Volumn 194, Issue 1, 2007, Pages 230-237

  Koh, Kwang Kon ^a   Quon, Michael J ^b   Han, Seung Hwan ^a   Ahn, Jeong Yeal ^a   Lee, Yonghee ^c   Shin, Eak Kyun ^a  

^a Gachon University College of Medicine   (South Korea)

^b National Institutes of Health   (United States)

^c Ewha Womans University   (South Korea)

Author keywords

ACE inhibitor; Hemostasis; Inflammation; Statins

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CD40 LIGAND; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRATE; PLACEBO; PROTHROMBIN; RAMIPRIL; SIMVASTATIN; THROMBOPLASTIN;

ADULT; ANALYSIS OF VARIANCE; ANTIATHEROGENIC ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; DRUG RESPONSE; DRUG TOLERABILITY; ENZYME ACTIVITY; FEMALE; HEMOSTASIS; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICHOLESTEREMIC AGENTS; C-REACTIVE PROTEIN; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOSTASIS; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MALONDIALDEHYDE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROTHROMBIN; RAMIPRIL; SIMVASTATIN; THROMBOPLASTIN;

EID: 34648851352     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.07.031     Document Type: Article

References (56)

1. Kario K., Matsuo T., Kobayashi H., et al. Activation of tissue factor-induced coagulation and endothelial cell dysfunction in non-insulin-dependent diabetic patients with microalbuminuria. Arterioscler Thromb Vasc Biol 15 (1995) 1114-1120
2. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
3. Effects of ramipril on cardiovascular, and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253-9.
4. Koh K.K., Son J.W., Ahn J.Y., et al. Comparative effects of diet and simvastatin on markers of thrombogenicity in patients with coronary artery disease. Am J Cardiol 91 (2003) 1231-1234
5. Vaughan D.E., Rouleau J.L., Ridker P.M., et al. Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators. Circulation 96 (1997) 442-447
6. Koh K.K. Effects of HMG-CoA reductase inhibitor on hemostasis. Int J Cardiol 76 (2000) 23-32
7. Brand K., Banka C.L., Mackman N., et al. Oxidized LDL enhances lipopolysaccharide-induced tissue factor expression in human adherent monocytes. Arterioscler Thromb 14 (1994) 790-797
8. Cermak J., Key N.S., Bach R.R., et al. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 82 (1993) 513-520
9. Girona J., La Ville A.E., Sola R., Plana N., and Masana L. Simvastatin decreases aldehyde production derived from lipoprotein oxidation. Am J Cardiol 83 (1999) 846-851
10. Kleinveld H.A., Demacker P.N.M., De Haan A.F.J., and Stalenhoff A.F.H. Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors. Eur J Clin Invest 23 (1993) 289-295
11. Colli S., Eligini S., Lalli M., et al. Vastatins inhibit tissue factor in cultured human macrophages. Arterioscler Thromb Vasc Biol 17 (1997) 265-272
12. Crutchley D.J., and Que B.G. Copper-induced tissue factor expression in human monocytic THP-1 cells and its inhibition by antioxidants. Circulation 92 (1995) 238-243
13. Ferro D., Basilli S., Alessandri C., et al. Simvastatin reduces monocyte tissue-factor expression type IIa hypercholesterolaemia. Lancet 350 (1997) 1222
14. Aikawa M., Voglic S.J., Sugiyama S., et al. Dietary lipid lowering reduces tissue factor expression in rabbit atheroma. Circulation 100 (1999) 1215-1222
15. Griendling K.K., Minieri C.A., Ollerenshaw J.D., and Alexander R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 74 (1994) 1141-1148
16. Herkert O., Diebold I., Brandes R.P., et al. NADPH oxidase mediates tissue factor-dependent surface procoagulant activity by thrombin in human vascular smooth muscle cells. Circulation 105 (2002) 2030-2036
17. Nishimura H., Tsuji H., Masuda H., et al. Angiotensin II increases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue type plasminogen activator or tissue factor pathway inhibitor in cultured rat aortic endothelial cells. Thromb Haemost 77 (1997) 1189-1195
18. Zaman A.K., Fujii S., Sawa H., et al. Angiotensin-converting enzyme inhibition attenuates hypofibrinolysis and reduces cardiac perivascular fibrosis in genetically obese diabetic mice. Circulation 103 (2001) 3123-3128
19. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 21 Suppl 1 (1998) S5-S22
20. Koh K.K., Quon M.J., Han S.H., et al. Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes. Hypertension 45 (2005) 1088-1093
21. Koh K.K., Quon M.J., Han S.H., et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 110 (2004) 3687-3692
22. Koh K.K., Quon M.J., Han S.H., et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 45 (2005) 1649-1653
23. Koh K.K., Chung W.J., Ahn J.Y., et al. Angiotensin II type 1 receptor blockers reduce tissue factor activity and plasminogen activator inhibitor type-1 antigen in hypertensive patients: a randomized, double-blind, placebo-controlled study. Atherosclerosis 177 (2004) 155-160
24. Koh K.K., Ahn J.Y., Jin D.K., et al. Significant differential effects of hormone therapy or tibolone on markers of cardiovascular disease in postmenopausal women: a randomized, double-blind, placebo-controlled, crossover study. Arterioscler Thromb Vasc Biol 23 (2003) 1889-1894
25. Koh K.K., Shin M.S., Sakuma I., et al. Effects of conventional or lower doses of hormone replacement therapy in postmenopausal women. Arterioscler Thromb Vasc Biol 24 (2004) 1516-1521
26. Koh K.K., Kang M.H., Jin D.K., et al. Vascular effects of estrogen in type II diabetic postmenopausal women. J Am Coll Cardiol 38 (2001) 1409-1415
27. Sever P.S., et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361 (2003) 1149-1158
28. Bosch J., et al. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 112 (2005) 1339-1346
29. Eto M., Kozai T., Cosentino F., Joch H., and Luscher T.F. Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. Circulation 105 (2002) 1756-1759
30. Muller D.N., Mervaala E.M., Dechend R., et al. Angiotensin II (AT(1)) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy. Am J Pathol 157 (2000) 111-122
31. Nickenig G., Sachinidis A., Michaelsen F., et al. Upregulation of vascular angiotensin II receptor gene expression by low-density lipoprotein in vascular smooth muscle cells. Circulation 95 (1997) 473-478
32. Nickenig G., Jung O., Strehlow K., et al. Hypercholesterolemia is associated with enhanced angiotensin AT1-receptor expression. Am J Physiol 272 (1997) H2701-H2707
33. Nickenig G., Baumer A.T., Temur Y., et al. Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men. Circulation 100 (1999) 2131-2134
34. Delbosc S., Cristol J.P., Descomps B., Mimran A., and Jover B. Simvastatin prevents angiotensin II-induced cardiac alteration and oxidative stress. Hypertension 40 (2002) 142-147
35. Li Z., Iwai M., Wu L., et al. Fluvastatin enhances the inhibitory effects of a selective AT1 receptor blocker, valsartan, on atherosclerosis. Hypertension 44 (2004) 758-763
36. Koh K.K., Ahn J.Y., Kim D.S., et al. Effect of hormone replacement therapy on tissue factor activity, C-reactive protein, and the tissue factor pathway inhibitor. Am J Cardiol 91 (2003) 371-373
37. Falciani M., Gori A.M., Fedi S., et al. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients. Thromb Haemost 79 (1998) 495-499
38. Kaikita K., Ogawa H., Yasue H., et al. Tissue factor expression on macrophages in coronary plaques in patients with unstable angina. Arterioscler Thromb Vasc Biol 17 (1997) 2232-2237
39. Soejima H., Ogawa H., Yasue H., et al. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation 99 (1999) 2908-2913
40. Ardissino D., Merlini P.A., Bauer K.A., et al. Coagulation activation and long-term outcome in acute coronary syndromes. Blood 102 (2003) 2731-2735
41. Sambola A., Osende J., Hathcock J., et al. Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 107 (2003) 973-977
42. Ferro D., Basili S., Alessandri C., Cara D., and Violi F. Inhibition of tissue-factor-mediated thrombin generation by simvastatin. Atherosclerosis 149 (2000) 111-116
43. Undas A., Brummel K.E., Musial J., Mann K.G., and Szczeklik A. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation 103 (2001) 2248-2253
44. Undas A., Celinska-Lowenhoff M., Brummel-Ziedins K.E., et al. Simvastatin given for 3 days can inhibit thrombin generation and activation of factor V and enhance factor Va inactivation in hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 25 (2005) 1524-1525
45. Koh K.K., Son J.W., Ahn J.Y., et al. Vascular effects of simvastatin combined with ramipril in hypercholesterolemic patients with coronary artery disease, compared with simvastatin alone: a randomized, double-blind, placebo-controlled, crossover study. Atherosclerosis 177 (2004) 147-153
46. Koh K.K., Han S.H., Chung W.-J., et al. Comparison of effects of losartan, irbesartan, and candesartan on flow-mediated brachial artery dilation and on inflammatory and thrombolytic markers in patients with systemic hypertension. Am J Cardiol 93 (2004) 1432-1435
47. Baetta R., Camera M., Comparato C., et al. Fluvastatin reduces tissue factor expression and macrophage accumulation in carotid lesions of cholesterol-fed rabbits in the absence of lipid lowering. Arterioscler Thromb Vasc Biol 22 (2002) 692-698
48. Schonbeck U., Mach F., Sukhova G.K., et al. CD40 ligation induces tissue factor expression in human vascular smooth muscle cells. Am J Pathol 156 (2000) 7-14
49. Mach F., Schonbeck U., Sukhova G.K., et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and machrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci USA 94 (1997) 1931-1936
50. Schönbeck U., and Libby P. CD40 signaling and plaque instability. Circ Res 89 (2001) 1092-1103
51. Aukrust P., Muller F., Ueland T., et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 100 (1999) 614-620
52. Heeschen C., Dimmeler S., Hamm C.W., et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med 348 (2003) 1104-1111
53. Tousoulis D., Antoniades C., Bosinakou E., et al. Effects of atorvastatin on reactive hyperaemia and the thrombosis-fibrinolysis system in patients with heart failure. Heart 91 (2005) 27-31
54. Vigna G.B., Donega P., Passaro A., et al. Post-prandial effects of gemfibrozil vs simvastatin in hypercholesterolemic subjects with borderline hypertriglyceridemia. Nutr Metab Cardiovasc Dis 9 (1999) 234-243
55. Remkova A., and Kratochvilova H. Effect of the angiotensin-converting enzyme inhibitor perindopril on haemostasis in essential hypertension. Blood Coagul Fibrinolysis 11 (2000) 641-644
56. Ekholm M., Wallen N.H., Johnsson H., Eliasson K., and Kahan T. Long-term angiotensin-converting enzyme inhibition with ramipril reduces thrombin generation in human hypertension. Clin Sci (Lond) 103 (2002) 151-155